Edesa Biotech, Inc. Cash Flow Statement
EDSA|7 years of annual SEC 10-K data (FY2014-FY2021)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Edesa Biotech, Inc. used $5M in operating cash flow and negative free cash flow of $5M in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|
| Net Income | -$6.4M | -$2.8M | -$5.0M | -$2.8M | -$8.4M | -$14.5M | -$5.5M |
| Depreciation & Amortization | $57.6K | $4.8K | $179.0K | $159.5K | $158.3K | $124.8K | $112.1K |
| Operating Cash Flow | -$5.0M | -$4.8M | -$4.7M | -$4.4M | -$4.3M | -$2.8M | -$3.9M |
| Capital Expenditures | $4.9K | $8.1K | $302.7K | $274.6K | $279.1K | $9.5K | $78.3K |
| Free Cash Flow | -$5.0M | -$4.9M | -$5.0M | -$4.7M | -$4.5M | -$2.8M | -$4.0M |
| FCF Margin | -1518.0% | -1181.4% | -2191.3% | -617.8% | -1221.5% | -514.3% | -1407.5% |